Indian clinical practice consensus guidelines for the management of oropharyngeal cancer: Update 2022

The aim of oropharyngeal cancer treatment should be to treat the disease while preserving speech and swallowing abilities. Early-stage disease is generally treated with surgery/radiotherapy (RT). A combination of chemotherapy and RT should be considered instead of RT alone for patients with locally...

Full description

Saved in:
Bibliographic Details
Published inCancer research, statistics, and treatment (Online) Vol. 7; no. Suppl 1; pp. S12 - S16
Main Authors Noronha, Vanita, Prabhash, Kumar, Babu, K Govind, Chaturvedi, Pankaj, Kuriakose, Moni, Birur, Praveen, Anand, Anil K, Kaushal, Ashish, Mahajan, Abhishek, Syiemlieh, Judita, Singhal, Manish, Gairola, Munish, Ramachandra, Prakash, Goyal, Sumit, John, Subashini, Nayyar, Rohit, Patil, Vijay M, Rao, Vishal, Roshan, Vikas, Rath, G.K.
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow 01.01.2024
Edition2
Subjects
Special Article
Adjuvant chemotherapy
Indian guidelines
oropharyngeal cancer
nimotuzumab
chemoradiation
recommendations
Online AccessGet full text
ISSN2590-3233
2590-3225
DOI10.4103/crst.crst_120_23

Cover

More Information
Summary:The aim of oropharyngeal cancer treatment should be to treat the disease while preserving speech and swallowing abilities. Early-stage disease is generally treated with surgery/radiotherapy (RT). A combination of chemotherapy and RT should be considered instead of RT alone for patients with locally advanced disease. Patients with locally advanced resectable disease can be treated with transoral or open resection of the primary + ipsilateral/bilateral neck dissection ± adjuvant chemoradiotherapy (CTRT)/adjuvant RT. In unresectable locally advanced disease, sequential induction chemotherapy (TPF [docetaxel, cisplatin, fluorouracil]) followed by locoregional treatment with RT or CTRT can be considered. Adding targeted therapies like nimotuzumab to cisplatin-based CTRT in locally advanced head-and-neck squamous cell carcinoma improves the progression-free survival, locoregional control, and disease-free survival without negatively impacting the quality of life.
ISSN:2590-3233
2590-3225
DOI:10.4103/crst.crst_120_23